Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
Saved in:
| Title: | Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study. |
|---|---|
| Authors: | Kowalyszyn, Ruben D.1 (AUTHOR), Fein, Luis E.2 (AUTHOR), Richardet, Martin E.3 (AUTHOR), Varela, Mirta S.4 (AUTHOR), Ortiz, Eduardo5 (AUTHOR), Micheri, Cristian6 (AUTHOR), Zarba, Juan J.7 (AUTHOR), Kahl, Susana8 (AUTHOR), Klimovsky, Ezequiel9 (AUTHOR) eklimovsky@quid-consulting.com, Federico, Andrea A.9 (AUTHOR), Cassini, Jorge H.10 (AUTHOR), Cortese, Gustavo11 (AUTHOR), Lago, Nestor12 (AUTHOR) |
| Source: | JCO Global Oncology. 3/24/2022, Vol. 8, p1-8. 8p. |
| Database: | Academic Search Ultimate |
| ISSN: | 26878941 |
|---|---|
| DOI: | 10.1200/GO.21.00276 |
